CryoPort, Inc. Common Stock (CYRX) is a publicly traded Industrials sector company. As of May 21, 2026, CYRX trades at $14.15 with a market cap of $670.85M and a P/E ratio of 10.38. CYRX moved +7.83% today. Year to date, CYRX is +43.13%; over the trailing twelve months it is +108.75%. Its 52-week range spans $4.58 to $14.36. Analyst consensus is strong buy with an average price target of $13.58. Rallies surfaces CYRX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Cryoport Q1 Revenue Jumps 16% to $47.8M, Raises Guidance to $196M: Cryoport's Q1 revenue rose 16% year-over-year to $47.8 million, driven by 26% growth in commercial cell and gene therapy services to $9.1 million, 18% life sciences services growth and 15% products growth. The company supported 766 clinical trials, reached 21 approved CGTs and raised full-year guidance to $192 million–$196 million.
| Metric | Value |
|---|---|
| Price | $14.15 |
| Market Cap | $670.85M |
| P/E Ratio | 10.38 |
| EPS | $1.34 |
| Dividend Yield | 0.00% |
| 52-Week High | $14.36 |
| 52-Week Low | $4.58 |
| Volume | 1.21K |
| Avg Volume | 0 |
| Revenue (TTM) | $182.94M |
| Net Income | $76.05M |
| Gross Margin | 47.19% |
7 analysts cover CYRX: 0 strong buy, 6 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $13.58.